Walter Weder
Extended resection for potentially operable patients with stage III non-small cell lung cancer after induction treatment.
Furrer K, Weder W, Eboulet E, Betticher D, Pless M, Stupp R, Krueger T, Perentes J, Schmid R, Lardinois D, Furrer M, Früh M, Peters S, Curioni-Fontecedro A, Stahel R, Rothschild S, Hayoz S, Opitz I. Extended resection for potentially operable patients with stage III non-small cell lung cancer after induction treatment. J Thorac Cardiovasc Surg 2022; 164:1587-1602.e5.
Apr 18, 2022Extended resection for potentially operable patients with stage III non-small cell lung cancer after induction treatment.
Apr 18, 2022J Thorac Cardiovasc Surg 2022; 164:1587-1602.e5
Furrer Katarzyna, Weder Walter, Eboulet Eric Innocents, Betticher Daniel, Pless Miklos, Stupp Roger, Krueger Thorsten, Perentes Jean Yannis, Schmid Ralph A, Lardinois Didier, Furrer Markus, Früh Martin, Peters Solange, Curioni-Fontecedro Alessandra, Stahel Rolf A, Rothschild Sacha I, Hayoz Stefanie, Opitz Isabelle
The Swiss Approach - feasibility of a national low-dose CT lung cancer screening program.
Jungblut L, von Garnier C, Puhan M, Tomonaga Y, Kaufmann C, Azzola A, Bürgi U, Bremerich J, Brutsche M, Christe A, Ebner L, Heverhagen J, Eich C, Franzen D, Schmitt-Opitz I, Schneiter D, Spieldenner J, Horwath N, Kohler M, Weder W, Lovis A, Meuli R, Menig M, Beigelmann-Aubry C, Niemann T, Stöhr S, Vock P, Senn O, Neuner-Jehle S, Selby K, Laures S, Otto S, Frauenfelder T. The Swiss Approach - feasibility of a national low-dose CT lung cancer screening program. Swiss Med Wkly 2022; 152
Apr 14, 2022The Swiss Approach - feasibility of a national low-dose CT lung cancer screening program.
Apr 14, 2022Swiss Med Wkly 2022; 152
Jungblut Lisa, von Garnier Christophe, Puhan Milo, Tomonaga Yuki, Kaufmann Cornel, Azzola Andrea, Bürgi Urs, Bremerich Jens, Brutsche Martin, Christe Andreas, Ebner Lukas, Heverhagen Johannes T, Eich Christine, Franzen Daniel, Schmitt-Opitz Isabelle, Schneiter Didier, Spieldenner Jörg, Horwath Nigel, Kohler Malcolm, Weder Walter, Lovis Alban, Meuli Reto, Menig Matthias, Beigelmann-Aubry Catherine, Niemann Tilo, Stöhr Susanna, Vock Peter, Senn Oliver, Neuner-Jehle Stefan, Selby Kevin, Laures Simin, Otto Sebastian, Frauenfelder Thomas
SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non-Small-Cell Lung Cancer-A Multicenter Single-Arm Phase II Trial
Rothschild S, Cathomas R, Ochsenbein A, Janthur W, Waibel C, Mach N, Froesch P, Buess M, Bohanes P, Godar G, Rusterholz C, Gonzalez M, Pless M, Mark M, Peters S, Zippelius A, Eboulet E, Savic Prince S, Betticher D, Bettini A, Früh M, Jörger M, Lardinois D, Gelpke H, Mauti L, Britschgi C, Weder W, Swiss Group for Clinical Cancer Research (SAKK). SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non-Small-Cell Lung Cancer-A Multicenter Single-Arm Phase II Trial. J Clin Oncol 2021; 39:2872-2880.
Jul 12, 2021SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non-Small-Cell Lung Cancer-A Multicenter Single-Arm Phase II Trial
Jul 12, 2021J Clin Oncol 2021; 39:2872-2880
Rothschild Sacha I, Cathomas Richard, Ochsenbein Adrian F, Janthur Wolf-Dieter, Waibel Christine, Mach Nicolas, Froesch Patrizia, Buess Martin, Bohanes Pierre, Godar Gilles, Rusterholz Corinne, Gonzalez Michel, Pless Miklos, Mark Michael, Peters Solange, Zippelius Alfred, Eboulet Eric I, Savic Prince Spasenija, Betticher Daniel, Bettini Adrienne, Früh Martin, Jörger Markus, Lardinois Didier, Gelpke Hans, Mauti Laetitia A, Britschgi Christian, Weder Walter, Swiss Group for Clinical Cancer Research (SAKK)
ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma
Opitz I, Greillier L, Hoda M, Klepetko W, Lacourt A, McElnay P, Maskell N, Mutti L, Pairon J, Van Schil P, van Meerbeeck J, Waller D, Weder W, Putora P, Galateau-Salle F, Fennell D, Scherpereel A, Berghmans T, Psallidas I, Glatzer M, Rigau D, Astoul P, Bölükbas S, Boyd J, Coolen J, De Bondt C, De Ruysscher D, Durieux V, Faivre-Finn C, Cardillo G. ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma. Eur J Cardiothorac Surg. 2020; 58:1-24.
Jul 1, 2020ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma
Jul 1, 2020Eur J Cardiothorac Surg. 2020; 58:1-24
Opitz Isabelle, Greillier Laurent, Hoda Mir Ali, Klepetko Walter, Lacourt Aude, McElnay Phil, Maskell Nick A, Mutti Luciano, Pairon Jean-Claude, Van Schil Paul, van Meerbeeck Jan P, Waller David, Weder Walter, Putora Paul Martin, Galateau-Salle Francoise, Fennell Dean A, Scherpereel Arnaud, Berghmans Thierry, Psallidas Ioannis, Glatzer Markus, Rigau David, Astoul Philippe, Bölükbas Servet, Boyd Jeanette, Coolen Johan, De Bondt Charlotte, De Ruysscher Dirk, Durieux Valérie, Faivre-Finn Corinne, Cardillo Giuseppe
Prognostic value of tumor-infiltrating lymphocytes (TILs) and their association with PD-L1 expression and DNA repair protein RAD51 in patients with resected non-small cell lung carcinoma
Gachechiladze M, Soltermann A, Rulle U, Weder W, Stahel R, Kolář Z, Shani I, Hajduch M, Vbrková J, Vojta P, Smičková P, Kolek V, Überall I, Skanderová D, Škarda J, Jörger M. Prognostic value of tumor-infiltrating lymphocytes (TILs) and their association with PD-L1 expression and DNA repair protein RAD51 in patients with resected non-small cell lung carcinoma. Lung Cancer 2020; 147:30-38.
Jun 23, 2020Prognostic value of tumor-infiltrating lymphocytes (TILs) and their association with PD-L1 expression and DNA repair protein RAD51 in patients with resected non-small cell lung carcinoma
Jun 23, 2020Lung Cancer 2020; 147:30-38
Gachechiladze Mariam, Soltermann Alex, Rulle Undine, Weder Walter, Stahel Rolf, Kolář Zdeněk, Shani Ilay, Hajduch Marian, Vbrková Jana, Vojta Petr, Smičková Petra, Kolek Vítězslav, Überall Ivo, Skanderová Daniela, Škarda Josef, Jörger Markus
ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma
Scherpereel A, Greillier L, Hoda M, Klepetko W, Lacourt A, McElnay P, Maskell N, Mutti L, Pairon J, Van Schil P, van Meerbeeck J, Waller D, Weder W, Cardillo G, Galateau-Salle F, Fennell D, Opitz I, Berghmans T, Psallidas I, Glatzer M, Rigau D, Astoul P, Bölükbas S, Boyd J, Coolen J, De Bondt C, De Ruysscher D, Durieux V, Faivre-Finn C, Putora P. ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma. Eur Respir J. 2020; 55
Jun 11, 2020ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma
Jun 11, 2020Eur Respir J. 2020; 55
Scherpereel Arnaud, Greillier Laurent, Hoda Mir Ali, Klepetko Walter, Lacourt Aude, McElnay Phil, Maskell Nick A, Mutti Luciano, Pairon Jean-Claude, Van Schil Paul, van Meerbeeck Jan P, Waller David, Weder Walter, Cardillo Giuseppe, Galateau-Salle Francoise, Fennell Dean, Opitz Isabelle, Berghmans Thierry, Psallidas Ioannis, Glatzer Markus, Rigau David, Astoul Philippe, Bölükbas Servet, Boyd Jeanette, Coolen Johan, De Bondt Charlotte, De Ruysscher Dirk, Durieux Valérie, Faivre-Finn Corinne, Putora Paul Martin
Pattern of failure after adjuvant radiotherapy following extrapleural pneumonectomy of pleural mesothelioma in the SAKK 17/04 trial
Riesterer O, Krayenbuehl J, Weder W, Sabrina Stark L, Zimmermann F, Nackaerts K, Zwahlen D, Mahmut Ozsahin E, Plasswilm L, Aebersold D, Xyrafas A, Stahel R, Ciernik I, Swiss Group for Clinical Cancer Research (SAKK). Pattern of failure after adjuvant radiotherapy following extrapleural pneumonectomy of pleural mesothelioma in the SAKK 17/04 trial. Radiother Oncol 2019; 138:121-125.
Jun 25, 2019Pattern of failure after adjuvant radiotherapy following extrapleural pneumonectomy of pleural mesothelioma in the SAKK 17/04 trial
Jun 25, 2019Radiother Oncol 2019; 138:121-125
Riesterer Oliver, Krayenbuehl Jerome, Weder Walter, Sabrina Stark L, Zimmermann Frank, Nackaerts Kristiaan, Zwahlen Daniel R, Mahmut Ozsahin E, Plasswilm Ludwig, Aebersold Daniel M, Xyrafas Alexandros, Stahel Rolf A, Ciernik I Frank, Swiss Group for Clinical Cancer Research (SAKK)
miR-625-3p and lncRNA GAS5 in Liquid Biopsies for Predicting the Outcome of Malignant Pleural Mesothelioma Patients Treated with Neo-Adjuvant Chemotherapy and Surgery
Kresoja-Rakic J, Cerciello F, Früh M, Stahel R, Weder W, Lam W, Martinez V, Minatel B, Ronner M, Kirschner M, Szpechcinski A, Felley-Bosco E. miR-625-3p and lncRNA GAS5 in Liquid Biopsies for Predicting the Outcome of Malignant Pleural Mesothelioma Patients Treated with Neo-Adjuvant Chemotherapy and Surgery. Noncoding RNA 2019; 5
Jun 17, 2019miR-625-3p and lncRNA GAS5 in Liquid Biopsies for Predicting the Outcome of Malignant Pleural Mesothelioma Patients Treated with Neo-Adjuvant Chemotherapy and Surgery
Jun 17, 2019Noncoding RNA 2019; 5
Kresoja-Rakic Jelena, Cerciello Ferdinando, Früh Martin, Stahel Rolf, Weder Walter, Lam Wan L, Martinez Victor D, Minatel Brenda, Ronner Manuel, Kirschner Michaela B, Szpechcinski Adam, Felley-Bosco Emanuela
Multimodal Treatment in Operable Stage III NSCLC: A Pooled Analysis on Long-Term Results of Three SAKK trials (SAKK 16/96, 16/00, and 16/01)
Früh M, Guckenberger M, Rothschild S, Lardinois D, Mach N, Mark M, Gautschi O, Thierstein S, Biaggi Rudolf C, Weder W, Stahel R, Matzinger O, Betticher D, Stupp R, Xyrafas A, Peters S, Ris H, Mirimanoff R, Ochsenbein A, Schmid R, Pless M. Multimodal Treatment in Operable Stage III NSCLC: A Pooled Analysis on Long-Term Results of Three SAKK trials (SAKK 16/96, 16/00, and 16/01). J Thorac Oncol 2018
Sep 26, 2018Multimodal Treatment in Operable Stage III NSCLC: A Pooled Analysis on Long-Term Results of Three SAKK trials (SAKK 16/96, 16/00, and 16/01)
Sep 26, 2018J Thorac Oncol 2018
Früh Martin, Guckenberger Matthias, Rothschild Sacha I, Lardinois Didier, Mach Nicholas, Mark Michael, Gautschi Oliver, Thierstein Sandra, Biaggi Rudolf Christine, Weder Walter, Stahel Rolf A, Matzinger Oscar, Betticher Daniel C, Stupp Roger, Xyrafas Alexandros, Peters Solange, Ris Hans Beat, Mirimanoff Rene Olivier, Ochsenbein Adrian F, Schmid Ralph, Pless Miklos
Prognostic and predictive value of loss of nuclear RAD51 immunoreactivity in resected non-small cell lung cancer patients
Gachechiladze M, Soltermann A, Weder W, Stahel R, Baty F, Kolář Z, Bouchal J, Langová K, Grygárková I, Kolek V, Škarda J, Jörger M. Prognostic and predictive value of loss of nuclear RAD51 immunoreactivity in resected non-small cell lung cancer patients. Lung Cancer 2017; 105:31-38.
Jan 18, 2017Prognostic and predictive value of loss of nuclear RAD51 immunoreactivity in resected non-small cell lung cancer patients
Jan 18, 2017Lung Cancer 2017; 105:31-38
Gachechiladze Mariam, Soltermann Alex, Weder Walter, Stahel Rolf, Baty Florent, Kolář Zdeněk, Bouchal Jan, Langová Kateřina, Grygárková Ivona, Kolek Vítězslav, Škarda Josef, Jörger Markus
Which Anesthesia Regimen Is Best to Reduce Morbidity and Mortality in Lung Surgery?: A Multicenter Randomized Controlled Trial
Beck-Schimmer B, Filipovic M, Schneiter D, Weder W, Vogt A, Stuber F, Risch T, Neff T, Seeberger M, Braun J, Bonvini J, Puhan M. Which Anesthesia Regimen Is Best to Reduce Morbidity and Mortality in Lung Surgery?: A Multicenter Randomized Controlled Trial. Anesthesiology 2016; 125:313-21.
Aug 1, 2016Which Anesthesia Regimen Is Best to Reduce Morbidity and Mortality in Lung Surgery?: A Multicenter Randomized Controlled Trial
Aug 1, 2016Anesthesiology 2016; 125:313-21
Beck-Schimmer Beatrice, Filipovic Miodrag, Schneiter Didier, Weder Walter, Vogt Andreas, Stuber Frank, Risch Tobias J, Neff Thomas A, Seeberger Manfred, Braun Julia, Bonvini John M, Puhan Milo
Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): a randomised, international, multicentre phase 2 trial
Stahel R, Caspar C, Eckhardt K, Schmid R, Aebersold D, Gautschi O, Nagel W, Töpfer M, Krayenbuehl J, Ribi K, Ciernik L, Mordasini C, Zippelius A, Riesterer O, Xyrafas A, Opitz I, Beyeler M, Ochsenbein A, Früh M, Cathomas R, Nackaerts K, Peters S, Mamot C, Weder W. Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): a randomised, international, multicentre phase 2 trial. Lancet Oncol 2015; 16:1651-8.
Nov 2, 2015Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): a randomised, international, multicentre phase 2 trial
Nov 2, 2015Lancet Oncol 2015; 16:1651-8
Stahel Rolf A, Caspar Clemens B, Eckhardt Katrin, Schmid Ralph A, Aebersold Daniel M, Gautschi Oliver, Nagel Wolfgang, Töpfer Michael, Krayenbuehl Jerome, Ribi Karin, Ciernik Llja F, Mordasini Carlo, Zippelius Alfred, Riesterer Oliver, Xyrafas Alexandros, Opitz Isabelle, Beyeler Michael, Ochsenbein Adrian, Früh Martin, Cathomas Richard, Nackaerts Kristiaan, Peters Solange, Mamot Christoph, Weder Walter
Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial
Pless M, Bijelovic M, Ochsenbein A, Meier U, Mamot C, Rauch D, Gautschi O, Betticher D, Mirimanoff R, Peters S, Roth A, Zippelius A, Stupp R, Ris H, Stahel R, Weder W, Thierstein S, Gerard M, Xyrafas A, Früh M, Cathomas R. Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial. Lancet 2015; 386:1049-56.
Aug 11, 2015Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial
Aug 11, 2015Lancet 2015; 386:1049-56
Pless Miklos, Bijelovic Milorad, Ochsenbein Adrian, Meier Urs R, Mamot Christoph, Rauch Daniel, Gautschi Oliver, Betticher Daniel C, Mirimanoff René-Olivier, Peters Solange, Roth Arnaud, Zippelius Alfred, Stupp Roger, Ris Hans-Beat, Stahel Rolf A, Weder Walter, Thierstein Sandra, Gerard Marie-Aline, Xyrafas Alexandros, Früh Martin, Cathomas Richard
Lung neuroendocrine tumors: correlation of ubiquitinylation and sumoylation with nucleo-cytosolic partitioning of PTEN
Collaud S, Tischler V, Atanassoff A, Wiedl T, Komminoth P, Öhlschlegel C, Weder W, Soltermann A. Lung neuroendocrine tumors: correlation of ubiquitinylation and sumoylation with nucleo-cytosolic partitioning of PTEN. BMC cancer 2015; 15:74.
Feb 20, 2015Lung neuroendocrine tumors: correlation of ubiquitinylation and sumoylation with nucleo-cytosolic partitioning of PTEN
Feb 20, 2015BMC cancer 2015; 15:74
Collaud Stéphane, Tischler Verena, Atanassoff Andrej, Wiedl Thomas, Komminoth Paul, Öhlschlegel Christian, Weder Walter, Soltermann Alex
Individual versus standard quality of life assessment in a phase II clinical trial in mesothelioma patients: feasibility and responsiveness to clinical changes
Ribi K, Stahel R, Ris H, Stupp R, Schmid R, Betticher D, Jörger M, Bodis S, Weder W, Schuller J, Bernhard J, Swiss Group for Clinical Cancer Research SAKK. Individual versus standard quality of life assessment in a phase II clinical trial in mesothelioma patients: feasibility and responsiveness to clinical changes. Lung cancer (Amsterdam, Netherlands) 2008; 61:398-404.
Sep 1, 2008Individual versus standard quality of life assessment in a phase II clinical trial in mesothelioma patients: feasibility and responsiveness to clinical changes
Sep 1, 2008Lung cancer (Amsterdam, Netherlands) 2008; 61:398-404
Ribi Karin, Stahel Rolf A, Ris Hans-Beat, Stupp Roger, Schmid Ralph A, Betticher Daniel, Jörger Markus, Bodis Stephan, Weder Walter, Schuller Jan C, Bernhard Jürg, Swiss Group for Clinical Cancer Research SAKK
Lung transplantation in Kartagener syndrome and situs inversus: potential of multidetector row computed tomography and three-dimensional postprocessing
Schertler T, Lardinois D, Boehm T, Weder W, Wildermuth S, Alkadhi H. Lung transplantation in Kartagener syndrome and situs inversus: potential of multidetector row computed tomography and three-dimensional postprocessing. The Journal of thoracic and cardiovascular surgery 2007; 134:814-5.
Sep 1, 2007Lung transplantation in Kartagener syndrome and situs inversus: potential of multidetector row computed tomography and three-dimensional postprocessing
Sep 1, 2007The Journal of thoracic and cardiovascular surgery 2007; 134:814-5
Schertler Thomas, Lardinois Didier, Boehm Thomas, Weder Walter, Wildermuth Simon, Alkadhi Hatem
Circulating deoxyribonucleic Acid as prognostic marker in non-small-cell lung cancer patients undergoing chemotherapy
Gautschi O, Stahel R, Betticher D, Jörger M, Weder W, Ratschiller D, Chassé E, Marx A, Jermann M, Huegli B, Bigosch C, Ziegler A. Circulating deoxyribonucleic Acid as prognostic marker in non-small-cell lung cancer patients undergoing chemotherapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004; 22:4157-64.
Oct 15, 2004Circulating deoxyribonucleic Acid as prognostic marker in non-small-cell lung cancer patients undergoing chemotherapy
Oct 15, 2004Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004; 22:4157-64
Gautschi Oliver, Stahel Rolf A, Betticher Daniel C, Jörger Markus, Weder Walter, Ratschiller Daniel, Chassé Eveline, Marx Arthur, Jermann Monika, Huegli Barbara, Bigosch Colette, Ziegler Annemarie
Management and costs of treating lung cancer patients in a university hospital
Dedes K, Szucs T, Bodis S, Jörger M, Lowy A, Russi E, Steinert H, Weder W, Stahel R. Management and costs of treating lung cancer patients in a university hospital. PharmacoEconomics 2004; 22:435-44.
Jan 1, 2004Management and costs of treating lung cancer patients in a university hospital
Jan 1, 2004PharmacoEconomics 2004; 22:435-44
Dedes Konstantin J, Szucs Thomas D, Bodis Stephan, Jörger Markus, Lowy Adam, Russi Erich W, Steinert Hans C, Weder Walter, Stahel Rolf A
Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non-small-cell lung cancer: a multicenter phase II trial
Betticher D, Stahel R, Weder W, Stupp R, Egli F, Furrer M, Honegger H, Wernli M, Cerny T, Spiliopoulos A, Roth A, Hsu Schmitz S, Tötsch M, Hansen E, Joss C, von Briel C, Schmid R, Pless M, Habicht J, Ris H. Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non-small-cell lung cancer: a multicenter phase II trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003; 21:1752-9.
May 1, 2003Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non-small-cell lung cancer: a multicenter phase II trial
May 1, 2003Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003; 21:1752-9
Betticher Daniel C, Stahel Rolf, Weder Walter, Stupp Roger, Egli Fritz, Furrer Markus, Honegger Hanspeter, Wernli Martin, Cerny Thomas, Spiliopoulos Anastase, Roth Arnaud D, Hsu Schmitz Shu-Fang, Tötsch Martin, Hansen Eva, Joss Christine, von Briel Christian, Schmid Ralph A, Pless Miklos, Habicht James, Ris Hans-Beat